市場調査レポート
商品コード
1439640
神経血管塞栓デバイス - 世界市場の考察、競合情勢、市場予測(2030年)Neurovascular Embolization Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
|||||||
カスタマイズ可能
適宜更新あり
|
神経血管塞栓デバイス - 世界市場の考察、競合情勢、市場予測(2030年) |
出版日: 2024年02月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
世界の神経血管塞栓デバイスの市場規模は、2023年に12億9,000万米ドル、2030年までに15億9,000万米ドルに達し、2024年~2030年の予測期間にCAGRで3.50%の成長が見込まれます。神経血管塞栓デバイスの需要の増加は主に、脳内出血や血管異常の有病率の増加、座りがちなライフスタイルによる脳動脈瘤や動静脈奇形(AVM)の増加に起因しています。さらに、老年人口の増加、高血圧の有病率の増加、さまざまな塞栓製品の発売などが、世界の神経血管塞栓デバイス市場の成長要因となっています。
神経血管塞栓デバイスの市場力学
神経血管塞栓デバイス市場は、人々の出血や脳動脈瘤の有病率が上昇していることから、現在勢いを増しています。公的医療制度であるNational Health Service(NHS)によると、喫煙、重度の頭部外傷、コカインの乱用、血圧の上昇など、脳動脈瘤の発症リスクを高める要因は数多くあり、神経血管塞栓デバイスの需要の増加につながる可能性があります。例えば、世界保健機関(WHO)が2023年に発表したデータによると、30~79歳の成人約12億8,000万人が世界中で高血圧症に罹患しています。また、高血圧患者の3分の2は低中所得国に住んでいるというデータもあります。
さらに、老年人口の拡大が続いていることも、今後数年間の神経血管塞栓デバイス市場に寄与する可能性があります。脳動脈瘤は30~60歳の成人に多く、男性よりも女性に多いからです。国連経済社会局人口部(UN DESA)が発表したWorld Population Ageing 2020 Highlightsによると、2020年に全世界で65歳以上の高齢者が7億2,700万人になると推定されています。同レポートによると、女性は高齢者の大部分を占め、特に高齢者では、2020年の65歳以上の世界人口の55%を占めています。
加えて、塞栓製品の承認も市場成長に寄与すると可能性があります。例えば、Terumo Corporationが開発した嚢内血流攪乱デバイスであるWoven EndoBridge(WEB)Aneurysm Embolization Systemは、2019年に米国FDAによって承認されました。
したがって、前述のすべての要因が、予測期間に神経血管塞栓デバイスの需要を強化すると見込まれます。
しかし、マイクロカテーテル、マイクロガイドワイヤー、コイルなどによる動脈瘤穿孔などの神経血管塞栓術に関連する特定の合併症が、市場を阻害する可能性が高いです。
前例のないCOVID-19パンデミックが神経血管塞栓デバイス市場を減速させています。これは、いくつかの国々でロックダウン、ソーシャルディスタンス規範、拡散防止措置が実施されたためです。さらに、手術の停止、くも膜下出血(SAH)の入院件数の減少、ウイルスの感染を防ぐための破裂動脈瘤のコイリング介入に加え、中でも、集中治療室(ICU)のほとんどがCOVID-19患者の大量流入で飽和したことから医療従事者の焦点がパンデミックの管理に移ったことも、市場に影響を与えました。
神経血管塞栓デバイス市場のセグメント分析
神経血管塞栓デバイス製品タイプセグメントでは、塞栓コイルが予測期間に大きな市場シェアを占めると予測されています。これは、塞栓コイルが広く入手可能であることや、先進の塞栓コイルを開発するメーカーによる取り組みの拡大によるものであり、患者集団におけるデバイスの採用率を高める可能性があります。例えば、2019年10月21日、Shape Memory Medicalは独自の形状記憶ポリマー(SMP)技術を特徴とするTrelliX® Embolic Coil SystemのCEマークを取得しました。
また、2019年9月17日、Wallaby Medicalは頭蓋内動脈瘤と動静脈奇形や動静脈瘻などのその他の神経血管異常の血管内塞栓術に使用することを想定し差別化された塞栓コイルシステムであるAvenir Coil SystemのCEマーク承認とFDA 510(k)認可を取得しました。本システムは、非常に安定したフレーミングコイル、大容量のフィリングコイル、非常に柔軟なフィニッシングコイルなど、あらゆる種類のコイルを提供します。
当レポートでは、世界の神経血管塞栓デバイス市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。
Neurovascular Embolization Devices Market By Product Type (Embolization Coils, Neurovascular Coil Assist Devices [Coil Assist Stents And Coil Assist Balloons], Liquid Embolization Systems, Flow Diversion Stents, Intrasaccular Flow Disruptor, Others), By End-User (Hospitals, Ambulatory Surgical Centers), by geography, is expected to expand at a static CAGR forecast till 2030 due to the rising cases of hemorrhages and brain aneurysm in the population across the globe and launch of embolization products in different regions worldwide
The global neurovascular embolization devices market was valued at USD 1.29 billion in 2023, growing at a CAGR of 3.50% during the forecast period from 2024 to 2030, to reach USD 1.59 billion by 2030. The rise in the demand for neurovascular embolization devices is predominantly attributed to the increasing prevalence of hemorrhages and the abnormalities in blood vessels present in the brain, increasing brain aneurysms and arteriovenous malformations (AVMs) due to sedentary lifestyles. Moreover, the rise in the geriatric population, increasing prevalence of high blood pressure, the launch of various embolization products, among others are the factors responsible for the global neurovascular embolization devices market growth.
Neurovascular Embolization Devices Market Dynamics:
The market for neurovascular embolization devices is gaining momentum at present owing to the rise in prevalence of hemorrhages and brain aneurysms among the population. According to the National Health Service (NHS), a publicly funded healthcare system, there are a lot of factors such as smoking, severe head injury, cocaine abuse, increase in blood pressure, among others that increases the risk of developing brain aneurysm among the population, thus would lead to an increase in the demand for neurovascular embolization devices. For instance, according to the data published by the World Health Organization (WHO) in the year 2023, approximately 1.28 billion adults aged between 30-79 years have hypertension across the globe. Also, the data mentioned that two-third of the population suffering from hypertension are living in low- and middle-income countries.
Furthermore, the ongoing expansion of the geriatric population would also contribute to the neurovascular embolization devices market in the forthcoming years. This is because brain aneurysm is common in adults between the ages of 30 and 60 and are more common in women than in men. According to the World Population Ageing 2020 Highlights published by the Population Division of the United Nations Department of Economic and Social Affairs (UN DESA), there were an estimated 727 million persons aged 65 years and above across the globe in the year 2020. As per the same report, women comprised of a majority of the older person, especially at an advanced age, and accounted for 55% of the global population aged 65 years and over in the year 2020.
In addition, approval of embolization products would also contribute to market growth. For instance, Woven EndoBridge (WEB) Aneurysm Embolization System, an Intrasaccular Flow Disruption Device developed by Terumo Corporation was approved by the US FDA in the year 2019.
Hence, all the aforementioned factors are anticipated to bolster the demand for neurovascular embolization devices during the forecasted period.
However, certain complications associated with the neurovascular embolization procedures such as procedural aneurysmal perforations by the microcatheter, micro-guidewire, or coil, among others are likely to impede the market.
The unprecedented COVID-19 pandemic has slowed down the market for neurovascular embolization devices. This is owing to the implementation of lockdown, the social distancing norms, and containment measures in several countries. Moreover, halt in surgeries, decreased volumes in subarachnoid hemorrhage (SAH) hospitalizations, and ruptured aneurysm coiling interventions to prevent the transmission of the virus, shifting focus of healthcare professionals to manage the pandemic as most of the intensive care units (ICU) were saturated with the massive influx of COVID-19 patients, among others also affected the market.
Neurovascular Embolization Devices Market Segment Analysis:
Neurovascular Embolization Devices Market By Product Type (Embolization Coils, Neurovascular Coil Assist Devices [Coil Assist Stents and Coil Assist Balloons], Liquid Embolization Systems, Flow Diversion Stents, Intrasaccular Flow Disruptor, Others), By End-User (Hospitals, Ambulatory Surgical Centers), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Neurovascular Embolization Devices product type segment, the embolization coil is anticipated to hold a significant market share during the forecasted period. This is due to the wide availability of embolization coils and growing initiatives by the manufacturers to develop advanced embolization coils which in turn would increase the adoption rate of the devices among the patient population. For instance, on October 21, 2019, Shape Memory Medical received CE Mark for the TrelliX® Embolic Coil System which features proprietary shape memory polymer (SMP) technology.
Also, on September 17, 2019, Wallaby Medical received CE Mark approval and FDA 510(k) clearance for its differentiated embolic coil system, the Avenir Coil System intended to use for endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae. The system offers a full line of coils including exceptional stable framing coils, extra volume filling coils, and ultra-soft finishing coils.
In addition, companies raising funds for the development and commercialization of neurovascular embolic coils are also expected to contribute to the segmental growth of the neurovascular embolization devices market. For instance, in July 2022, Zylox-Tonbridge Medical Technology Co., Ltd., a neuro- and peripheral-vascular interventional medical device company raised USD 329 million to support the development and commercialization of its core products which include neurovascular embolization coils, a micro catheter for coiling, among others.
Thus, all the above-mentioned factors would boost the market for neurovascular embolization devices in the upcoming years.
North America is expected to dominate the overall Neurovascular Embolization Devices Market:
Among all the regions, North America is expected to occupy a major share in the overall neurovascular embolization devices market during the forthcoming years. This domination is owing to the increasing prevalence of the target population in the region. Moreover, the presence of key market players and the recent launch of embolization products in the region is anticipated to propel the neurovascular embolization market.
For instance, as per the 2022 data of the Brain Aneurysm Foundation, an estimated 6.5 million people in the US have an unruptured brain aneurysm in the year 2020 and about 30,000 people suffer from a brain aneurysm rupture each year.
In addition, an increase in government initiatives and funding to support research for brain aneurysms in the country would also increase the regional market for neurovascular embolization devices. For instance, as per the bill presented in the 117 session on March 03, 2022, USD 10,000,000 has been funded by the government to conduct or support further comprehensive research on unruptured intracranial aneurysms for each of fiscal years 2022 through 2028 which will remain available through September 30, 2029.
Moreover, strategic business activities and approval of products in the region would also boost the regional market for neurovascular embolization devices. For instance, in the year 2020, Kaneka Corporation received FDA approval for its new brain aneurysm Embolization coil, i-ED COIL(TM).
Hence, the interplay of all the aforementioned factors will bolster the demand for the neurovascular embolization market in the region during the forecasted period.
Furthermore, the Asia-pacific region has future potential for the neurovascular embolization devices market. This is owing to the rising sedentary lifestyle such as consumption of alcohol, increase in aging population, growing head injuries, among others. For instance, as per the World Bank Group 2022 data, in the year 2020, China had 168,863,853 population aged 65 and above.
In addition, strategic business activity to expand the domestic market in the APAC region would also contribute to the neurovascular embolization devices market. For instance, in the year 2020, Genesis MedTech Group acquired Minitech Medical, a leading domestic enterprise in the neurovascular industry, and successfully developed and launched its first domestically-made intracranial embolization stent. Hence, all of these factors are likely to make APAC the fastest market for neurovascular embolization devices during the forecasted period.
Neurovascular Embolization Devices Market Key Players:
Some of the key market players operating in the Neurovascular Embolization Devices market include Medtronic, Stryker, MicroVention, Inc. (Terumo Corporation), Johnson & Johnson Services, Inc., Penumbra, Inc., Balt, B. Braun Melsungen AG, Acandis GmbH, Wallaby Medical., Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology Co., Ltd., Spartan Micro, Inc., KANEKA CORPORATION, Lepu Medical Technology(Beijing)Co., Ltd., Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, phenox GmbH, Merit Medical Systems., Perflow Medical Ltd., MicroPort Scientific Corporation., Cerus Endovascular, Rapid Medical, among others.
Recent Developmental Activities in the Neurovascular Embolization Devices Market:
In October 2020, Shanghai MicroPort NeuroTech Co., Ltd. ("MicroPort® NeuroTech") received the registration certificates issued by China's National Medical Products Administration (NMPA) for its proprietary NUMEN Coil Embolization System and NUMEN FR Coil Detachment System for the treatment of cerebral aneurysms through minimally invasive neurovascular intervention.
In April 2020, Cerus Endovascular received CE Mark approval for its Neqstent Coil Assisted Flow Diverter device designed for the treatment of intracranial aneurysms.
In May 2019, Rapid Medical, a company focused on the development of next-generation neurovascular devices, received FDA clearance for the Comaneci device as a temporary coil embolization assist device.
Key Takeaways from the Neurovascular Embolization Devices Market Report Study
Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Neurovascular Embolization Devices market.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the Global Neurovascular Embolization Devices Market.
Various opportunities available for the other competitor in the Neurovascular Embolization Devices Market space.
What are the top-performing segments in 2023? How these segments will perform in 2030.
Which are the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Neurovascular Embolization Devices market growth in the coming future?
Target Audience who can be benefited from the Neurovascular Embolization Devices Market Report Study
Neurovascular Embolization Devices providers
Research organizations and consulting companies
Neurovascular Embolization Devices-related organization, association, forum, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in Neurovascular Embolization Devices
Various End-users who want to know more about the Neurovascular Embolization Devices Market and latest technological developments in the Neurovascular Embolization Devices market.
Frequently Asked Questions for the Neurovascular Embolization Devices Market:
A neurovascular embolization device is an intravascular implant intended to permanently occlude blood flow to cerebral aneurysms and cerebral arteriovenous malformations.
The global neurovascular embolization devices market was valued at USD 1.29 billion in 2023, growing at a CAGR of 3.50% during the forecast period from 2024 to 2030, to reach USD 1.59 billion by 2030.
The major factors driving the demand for Neurovascular Embolization Devices are the rising cases of hemorrhage stroke, brain aneurysm, and cerebral arteriovenous malformations due to sedentary lifestyles such as excessive consumption of alcohol, serious head injuries, and others. In addition, the rising prevalence of high blood pressure, growing product approval, and increase in the aging population, among others are also expected to boost the market.
Some of the key market players operating in the Neurovascular Embolization Devices market include Medtronic, Stryker, MicroVention, Inc. (Terumo Corporation), Johnson & Johnson Services, Inc., Penumbra, Inc., Balt, B. Braun Melsungen AG, Acandis GmbH, Wallaby Medical., Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology Co., Ltd., Spartan Micro, Inc., KANEKA CORPORATION, Lepu Medical Technology(Beijing)Co., Ltd., Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, phenox GmbH, Merit Medical Systems., Perflow Medical Ltd., MicroPort Scientific Corporation., Cerus Endovascular, Rapid Medical, among others.
Among all the regions, North America is expected to occupy a major share in the overall neurovascular embolization devices market during the forthcoming years. This domination is owing to the increasing prevalence of the target population in the region. Moreover, the presence of key market players and the recent launch of embolization products in the region is anticipated to propel the neurovascular embolization market.